NCT03061656 is a Phase 2 clinical trial of Cyclophosphamide in High Risk Neuroblastoma, sponsored by Samsung Medical Center.

Who is sponsoring NCT03061656?

NCT03061656 is sponsored by Samsung Medical Center.

What drugs are being tested in NCT03061656?

Interventions in NCT03061656: Cyclophosphamide, Carboplatin, Etoposide, 131I-MIBG, Thiotepa, Melphalan.

What condition does NCT03061656 study?

NCT03061656 studies High Risk Neuroblastoma.

Is NCT03061656 still recruiting?

NCT03061656 is currently status unknown. Last updated 18 September 2018.

Last reviewed 2018-09-18 · How we verify

NCT03061656

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma

Status unknown Phase 2 Last updated 18 September 2018

What this trial tests

Phase 2 trial testing Cyclophosphamide in High Risk Neuroblastoma in 40 participants. Status unknown.

Timeline

1 January 2009

Primary endpoint
31 December 2013

31 December 2018

Quick facts

Lead sponsor	Samsung Medical Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 January 2009
Primary completion	31 December 2013
Estimated completion	31 December 2018

Drugs / interventions tested

Cyclophosphamide (cyclophosphamide) — full drug profile →
Carboplatin (Carboplatin) — full drug profile →
Etoposide (etoposide) — full drug profile →
131I-MIBG
Thiotepa — full drug profile →
Melphalan

Conditions studied

High Risk Neuroblastoma — all drugs for High Risk Neuroblastoma →

Sponsor

Samsung Medical Center

Who can join

Under 21, any sex, with High Risk Neuroblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and toxicity of tandem HDCT/ASCT including high-dose 131I-metaiodobenzylguanidine (MIBG) treatment. In the present study, a single arm trial of tandem HDCT/ASCT will be carried out.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Incorporation of high-dose <sup>131</sup>I-metaiodobenzylguanidine treatment into tandem high-dose chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma: results of the SMC NB-2009 study.
Lee JW, Lee S, Cho HW, Ma Y, et al · · 2017 · cited 28× · PMID 28511709 · DOI 10.1186/s13045-017-0477-0

Verify or expand the search:

Other trials of Cyclophosphamide

Trials testing the same drug.

NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07509008 — Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Manageme · Phase 1, PHASE2 · not yet recruiting
NCT07444632 — Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/ · Phase 1 · not yet recruiting
NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
NCT07437963 — Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatmen · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for High Risk Neuroblastoma

Currently open trials in the same condition.

NCT07278674 — Clinical Study of Eflornithine After Immunotherapy for High-risk Neuroblastoma（CSHEIN） · active not recruiting
NCT03794349 — Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed · Phase 2 · active not recruiting
NCT03786783 — Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastom · Phase 2 · active not recruiting

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03061656 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 18 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03061656.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing